Atezolizumab Plus R-CHOP Deemed Unworthy of Additional Study in Diffuse Large B-Cell Lymphoma
Results of a phase 1/2 trial suggest the combination of atezolizumab and R-CHOP does not warrant further study in DLBCL, according to researchers.
All articles by Waseem Qureshi
Outcomes After BTK Inhibitor Failure in Rel/Ref Mantle Cell Lymphoma
A real-world study provides a benchmark for survival in MCL patients for whom BTK inhibitor treatment has failed, according to researchers.
Relatlimab-Nivolumab Combo Deemed Promising in Resectable Melanoma
Relatlimab plus nivolumab yields a high pathologic complete response rate in resectable stage III or oligometastatic stage IV melanoma, a phase 2 study suggests.
Cilta-Cel May Fulfill Unmet Need for Multiple Myeloma Patients in China
Ciltacabtagene autoleucel had a favorable risk-benefit profile in a study of Chinese patients with relapsed/refractory multiple myeloma, according to researchers.
Fewer Serious Adverse Events Reported in Cancer Trials During COVID-19 Pandemic
Serious adverse events were reported less frequently among patients enrolled in cancer trials during the first 2 years of the COVID-19 pandemic than among patients enrolled prior to the pandemic.
Some Women With Early-Stage Breast Cancer May Safely Forgo Surgery
Omission of surgery may be possible for women with early-stage breast cancer who are exceptional responders to neoadjuvant systemic therapy.
Radiation to Celiac Plexus Reduces Pancreatic Cancer-Associated Pain
Delivery of radiation to the celiac plexus can decrease pain and opioid use among patients with pancreatic cancer, a phase 2 study suggests.
Concurrent Radiation Boost Comparable to Sequential Boost in High-Risk Breast Cancer
A concurrent radiation boost produces comparable outcomes as a sequential boost in patients with high-risk breast cancer, a phase 3 study suggests.
Cabozantinib Improves PFS in Radioiodine-Refractory Differentiated Thyroid Cancer
Cabozantinib prolongs progression-free survival in patients with previously treated radioiodine-refractory differentiated thyroid cancer, a phase 3 trial suggests.
S-1-Based Chemoradiotherapy Improves Outcomes in Elderly Patients With Esophageal Squamous Cell Carcinoma
Adding oral S-1 chemotherapy to radiotherapy can improve outcomes in elderly patients with inoperable esophageal squamous cell carcinoma.
- Loading...
Loading...
Next post in ASTRO 2022
Loading... 
Loading...